Genetic Determinants Differences between Vibrio cholerae Biotypes
... the C-terminal region of the pilin, where epitopes are recognized by the protective monoclonal antib-odies map (54-56). Although 75% similarity at the nucleotide level have been observed in the major pilin protein TcpA known to be di erent significantly between the El Tor and classical biotypes (53, ...
... the C-terminal region of the pilin, where epitopes are recognized by the protective monoclonal antib-odies map (54-56). Although 75% similarity at the nucleotide level have been observed in the major pilin protein TcpA known to be di erent significantly between the El Tor and classical biotypes (53, ...
"RNA Interference in Caenorhabditis elegans".
... necessary to deliver dsRNA directly to the germline, however, injections need not be performed at high magnification or using differential interference contrast microscopy (DIC; Nomarski optics). Therefore, even if expertise in C. elegans microinjection is unavailable, it should be possible to maste ...
... necessary to deliver dsRNA directly to the germline, however, injections need not be performed at high magnification or using differential interference contrast microscopy (DIC; Nomarski optics). Therefore, even if expertise in C. elegans microinjection is unavailable, it should be possible to maste ...
Topical Negative Pressure in Wound Care Effectiveness and
... contaminated wounds. An open wound invariably becomes colonized by bacteria because there is no protective skin barrier to prevent bacterial adherence to the exposed tissue. Although colonization does not preclude healing, it can be significantly delayed when there is clinical infection (22). Clinic ...
... contaminated wounds. An open wound invariably becomes colonized by bacteria because there is no protective skin barrier to prevent bacterial adherence to the exposed tissue. Although colonization does not preclude healing, it can be significantly delayed when there is clinical infection (22). Clinic ...
2014 Update
... side effects (i.e., constipation) was reported in poor vs. extensive metabolizers,13 whereas a later study by the same group of investigators found that central side effects (e.g., sedation, nausea, and dry mouth) did not differ between poor and extensive metabolizers.11 By contrast, pharmacokinetic ...
... side effects (i.e., constipation) was reported in poor vs. extensive metabolizers,13 whereas a later study by the same group of investigators found that central side effects (e.g., sedation, nausea, and dry mouth) did not differ between poor and extensive metabolizers.11 By contrast, pharmacokinetic ...
Anticholinergic therapy for acute asthma in children (Review)
... anticholinergics with beta2 -agonists. Children on anticholinergics alone were significantly more likely to experience treatment failure than those on beta2 -agonists (odds ratio (OR) 2.27; 95% CI 1.08 to 4.75). We also found data from four trials on 173 children comparing children on anticholinergi ...
... anticholinergics with beta2 -agonists. Children on anticholinergics alone were significantly more likely to experience treatment failure than those on beta2 -agonists (odds ratio (OR) 2.27; 95% CI 1.08 to 4.75). We also found data from four trials on 173 children comparing children on anticholinergi ...
Studies on warfarin treatment with emphasis on inter
... alfalfa, a plant rich in vitamin K, provided a curative effect against the sweet clover disease, although he wrongly denied that vitamin K itself could function as an antidote for the disease. The newly discovered vitamin K [4,5] was concurrently attracting an increasing interest, parallel to the a ...
... alfalfa, a plant rich in vitamin K, provided a curative effect against the sweet clover disease, although he wrongly denied that vitamin K itself could function as an antidote for the disease. The newly discovered vitamin K [4,5] was concurrently attracting an increasing interest, parallel to the a ...
... data on 575 adults. Urticarial rash is transient and is therefore often not present at the day of examination. Therefore, the diagnosis relies chiefly on patient recollection and on the capability of the interviewing physician to obtain the correct information about past symptoms. Although we collec ...
2012 American College of Rheumatology Therapy and Antiinflammatory Prophylaxis of
... Urate-lowering therapy (ULT) is a cornerstone in the management of gout (1) and, when effective in lowering serum urate, is associated with a decreased risk of acute gouty attacks (6). However, during the initial phase of ULT, there is an early increase in acute gout attacks, which has been hypothes ...
... Urate-lowering therapy (ULT) is a cornerstone in the management of gout (1) and, when effective in lowering serum urate, is associated with a decreased risk of acute gouty attacks (6). However, during the initial phase of ULT, there is an early increase in acute gout attacks, which has been hypothes ...
RMHP Prior Authorization List Effective October 1, 2015 rev 7/18/2016
... review. Failure to obtain authorization for services determined by RMHP to be experimental or investigational will result in denial of payment. These services include, but are not limited to, new procedures without proven effectiveness, clinical trials and studies, miscellaneous codes, and Category ...
... review. Failure to obtain authorization for services determined by RMHP to be experimental or investigational will result in denial of payment. These services include, but are not limited to, new procedures without proven effectiveness, clinical trials and studies, miscellaneous codes, and Category ...
Plasminogen deficiency - National Hemophilia Foundation
... levels is variable in reported cases. The largest study of plasminogen deficiency investigated and reported the genetic defect in 50 patients. In this report, plasminogen activity ranged from 4% to 51% [10]. Other reports have been consistent with these results [1]. Interestingly, these reports deli ...
... levels is variable in reported cases. The largest study of plasminogen deficiency investigated and reported the genetic defect in 50 patients. In this report, plasminogen activity ranged from 4% to 51% [10]. Other reports have been consistent with these results [1]. Interestingly, these reports deli ...
Implementing an Antibiotic Stewardship Program
... Department of Medicine, Weill Cornell Medical Center/New York–Presbyterian Hospital, New York, New York; 6Department of Internal Medicine, Texas A&M Health Science Center College of Medicine, Houston; 7Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention, Atlanta, Geo ...
... Department of Medicine, Weill Cornell Medical Center/New York–Presbyterian Hospital, New York, New York; 6Department of Internal Medicine, Texas A&M Health Science Center College of Medicine, Houston; 7Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention, Atlanta, Geo ...
Type 1 Diabetes: Etiology, Immunology, and Therapeutic Strategies
... when they see a physician for clinical signs such as excessive thirst, urination, and hunger. These symptoms result from the underlying hyperglycemia that is in turn caused by insufficient insulin functionality. In T2D, which is usually associated with obesity or older age, this is mostly the result ...
... when they see a physician for clinical signs such as excessive thirst, urination, and hunger. These symptoms result from the underlying hyperglycemia that is in turn caused by insufficient insulin functionality. In T2D, which is usually associated with obesity or older age, this is mostly the result ...
About Neurofibromatosis 1 - Children`s Tumor Foundation
... they may have passed on NF1 to their children), even if they have no obvious signs. An examination by a physician familiar with the signs of NF1 is usually the best way to determine whether the disorder is present. If a family member is found to have a few features of NF1 but not enough to make a di ...
... they may have passed on NF1 to their children), even if they have no obvious signs. An examination by a physician familiar with the signs of NF1 is usually the best way to determine whether the disorder is present. If a family member is found to have a few features of NF1 but not enough to make a di ...
Diagnosis and treatment of nicotine dependence with emphasis on
... myocardial infarction. An important aspect of the effects of nicotine is the delivery system. A cigarette delivers bolus doses of nicotine rapidly into the pulmonary circulation, producing peak concentrations in the heart and brain five times greater than those produced by other nicotine delivery sys ...
... myocardial infarction. An important aspect of the effects of nicotine is the delivery system. A cigarette delivers bolus doses of nicotine rapidly into the pulmonary circulation, producing peak concentrations in the heart and brain five times greater than those produced by other nicotine delivery sys ...
C57BL/6 - Envigo
... Scna = alpha synuclein; one in a family of structurally related proteins that are prominently expressed in the brain, particularly in areas associated with learning and adaption. The exact function of alpha synuclein is not yet known. Mnrn1 = multimerin 1; multimerin 1 is a stored platelet and endot ...
... Scna = alpha synuclein; one in a family of structurally related proteins that are prominently expressed in the brain, particularly in areas associated with learning and adaption. The exact function of alpha synuclein is not yet known. Mnrn1 = multimerin 1; multimerin 1 is a stored platelet and endot ...
canadian thoracic society 2012 guideline update
... ICS remain the foundation of chronic maintenance pharmacotherapy for patients with asthma in all age groups. Leukotriene receptor antagonists (LTRAs) are acceptable, second-line, daily monotherapy for children 6 years of age and over and adults. Failure to achieve acceptable asthma control on low do ...
... ICS remain the foundation of chronic maintenance pharmacotherapy for patients with asthma in all age groups. Leukotriene receptor antagonists (LTRAs) are acceptable, second-line, daily monotherapy for children 6 years of age and over and adults. Failure to achieve acceptable asthma control on low do ...
Pegylated interferon α-2a and -2b with ribavirin in treatment of
... he research findings from the NHS R&D Health Technology Assessment (HTA) Programme directly influence key decision-making bodies such as the National Institute for Clinical Excellence (NICE) and the National Screening Committee (NSC) who rely on HTA outputs to help raise standards of care. HTA findi ...
... he research findings from the NHS R&D Health Technology Assessment (HTA) Programme directly influence key decision-making bodies such as the National Institute for Clinical Excellence (NICE) and the National Screening Committee (NSC) who rely on HTA outputs to help raise standards of care. HTA findi ...
Asymmetries in Retrieval of Gene Function Information
... of the source followed by a slash followed by an accession number and can be searched with one or both components, e.g., genbank [si], AF001892 [si], genbank/AF001892 [si]. The SI field and the Entrez sequence database links are not linked. The PubMed links to these databases are created from the re ...
... of the source followed by a slash followed by an accession number and can be searched with one or both components, e.g., genbank [si], AF001892 [si], genbank/AF001892 [si]. The SI field and the Entrez sequence database links are not linked. The PubMed links to these databases are created from the re ...
Gene therapy
Gene therapy is the therapeutic delivery of nucleic acid polymers into a patient's cells as a drug to treat disease. Gene therapy could be a way to fix a genetic problem at its source. The polymers are either expressed as proteins, interfere with protein expression, or possibly correct genetic mutations.The most common form uses DNA that encodes a functional, therapeutic gene to replace a mutated gene. The polymer molecule is packaged within a ""vector"", which carries the molecule inside cells.Gene therapy was conceptualized in 1972, by authors who urged caution before commencing human gene therapy studies. By the late 1980s the technology had already been extensively used on animals, and the first genetic modification of a living human occurred on a trial basis in May 1989 , and the first gene therapy experiment approved by the US Food and Drug Administration (FDA) occurred on September 14, 1990, when Ashanti DeSilva was treated for ADA-SCID. By January 2014, some 2,000 clinical trials had been conducted or approved.Early clinical failures led to dismissals of gene therapy. Clinical successes since 2006 regained researchers' attention, although as of 2014, it was still largely an experimental technique. These include treatment of retinal disease Leber's congenital amaurosis, X-linked SCID, ADA-SCID, adrenoleukodystrophy, chronic lymphocytic leukemia (CLL), acute lymphocytic leukemia (ALL), multiple myeloma, haemophilia and Parkinson's disease. Between 2013 and April 2014, US companies invested over $600 million in the field.The first commercial gene therapy, Gendicine, was approved in China in 2003 for the treatment of certain cancers. In 2011 Neovasculgen was registered in Russia as the first-in-class gene-therapy drug for treatment of peripheral artery disease, including critical limb ischemia.In 2012 Glybera, a treatment for a rare inherited disorder, became the first treatment to be approved for clinical use in either Europe or the United States after its endorsement by the European Commission.